We sought to determine whether a cystic fibrosis transmembrane conductance regulator (CFTR) mRNA could be administered to the fetus via the transamniotic route as a potential strategy for the perinatal management of cystic fibrosis-associated meconium ileus. This evidence concerns the gene CFTR and intestinal obstruction in the newborn due to guanylate cyclase 2C deficiency.